AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32167230 — intervention group
Group type: COMPARATOR
Intervention: Gender effect on body hair removal
Number of subjects: 2510
Study 32167230 — intervention group
Group type: COMPARATOR
Intervention: Demographic factors associated with body hair removal
Number of subjects: 2510
Study 32167230 — intervention group
Group type: COMPARATOR
Intervention: Body image differences
Number of subjects: 2510
Study 36202797 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram + ICBT
Number of subjects: 24
Study 36202797 — intervention group
Group type: COMPARATOR
Intervention: placebo + ICBT
Number of subjects: 24
Study 34251097 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenazopyridine 200 mg 3 times a day for 2 days and fosfomycin trometamol 3 g once
Number of subjects: 152
Study 34251097 — intervention group
Group type: COMPARATOR
Intervention: Fosfomycin trometamol 3 g once and drotaverin 80 mg 3 times a day for 2 days
Number of subjects: 152
Study 34251097 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenazopyridine and fosfomycin
Number of subjects: 152
Study 34251097 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenazopyridine
Number of subjects: 152
Study 33384390 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalated adaptive tumour‐focused radiotherapy (DART)
Number of subjects: 120
Study 33384390 — intervention group
Group type: COMPARATOR
Intervention: Standard/control whole bladder single plan radiotherapy
Number of subjects: 120
Study 33384390 — intervention group
Group type: COMPARATOR
Intervention: Standard dose adaptive tumour‐focused radiotherapy
Number of subjects: 120
Study 33079303 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-layer continuous suturing (SCS)
Number of subjects: 182
Study 33079303 — intervention group
Group type: COMPARATOR
Intervention: Modified Blumgart anastomosis (MBA)
Number of subjects: 182
Study 34915528 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 G biopsy needle (Bard MC l616)
Number of subjects: 123
Study 34915528 — intervention group
Group type: COMPARATOR
Intervention: 18 G biopsy needle (Bard MC l820)
Number of subjects: 123
Study 33879663 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement therapy (ONS)
Number of subjects: 0
Study 33879663 — intervention group
Group type: COMPARATOR
Intervention: Traditional diet
Number of subjects: 0
Study 34821510 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran plus ticagrelor
Number of subjects: 0
Study 34821510 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran plus clopidogrel
Number of subjects: 0
Study 33619595 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic common bile duct exploration (LCBDE)
Number of subjects: 334
Study 33619595 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic common bile duct exploration (LCBDE) with laser lithotripsy
Number of subjects: 334
Study 33619595 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic common bile duct exploration (LCBDE) with primary closure
Number of subjects: 334
Study 33619595 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic common bile duct exploration (LCBDE) with T-tube drainage
Number of subjects: 334
Study 32917627 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic re-esterified triglyceride (rTG) form of omega-3 fatty acids for 2 months
Number of subjects: 66
Study 33380582 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week continuous supplementation of hydrogen-rich water (HW), 500 mL daily on weekdays (total 5 L)
Number of subjects: 0
Study 33380582 — intervention group
Group type: COMPARATOR
Intervention: Single intake of hydrogen-rich water (HW), 500 mL
Number of subjects: 0
Study 35820703 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided technique with low blood pressure (BP)
Number of subjects: 20
Study 35820703 — intervention group
Group type: COMPARATOR
Intervention: Palpation-guided technique with high BP
Number of subjects: 20
Study 35820703 — intervention group
Group type: COMPARATOR
Intervention: Palpation-guided technique with low BP
Number of subjects: 20
Study 35820703 — intervention group
Group type: EXPERIMENTAL
Intervention: US technique
Number of subjects: 20
Study 35820703 — intervention group
Group type: COMPARATOR
Intervention: Palpation high BP
Number of subjects: 20
Study 35820703 — intervention group
Group type: COMPARATOR
Intervention: Palpation low BP
Number of subjects: 20
Study 33655920 — intervention group
Group type: EXPERIMENTAL
Intervention: Early use of MRI or CT
Number of subjects: 0
Study 33655920 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 35030509 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm-themed messages
Number of subjects: 501
Study 35030509 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness-themed messages
Number of subjects: 501
Study 35030509 — intervention group
Group type: EXPERIMENTAL
Intervention: Images of couples
Number of subjects: 501
Study 35030509 — intervention group
Group type: EXPERIMENTAL
Intervention: Images of individuals
Number of subjects: 501
Study 34170943 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive fluid administration (clear fluids 0.75-1.0 times the volume of blood lost)
Number of subjects: 252
Study 34170943 — intervention group
Group type: COMPARATOR
Intervention: Liberal fluid administration (clear fluids 1.5-2.0 times the volume of blood lost)
Number of subjects: 252
Study 34170943 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive fluid administration
Number of subjects: 252
Study 34170943 — intervention group
Group type: COMPARATOR
Intervention: Liberal fluid administration
Number of subjects: 252
Study 33213284 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodyweight resistance exercise breaks every 30 minutes (REX)
Number of subjects: 12
Study 33213284 — intervention group
Group type: COMPARATOR
Intervention: Uninterrupted sitting (SIT)
Number of subjects: 12
Study 36185576 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzheng Guben decoction with continuous nursing intervention
Number of subjects: 72
Study 36185576 — intervention group
Group type: COMPARATOR
Intervention: Routine intervention and chemotherapy
Number of subjects: 72
Study 36185576 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative urinary incontinence and other complications
Number of subjects: 72
Study 36185576 — intervention group
Group type: EXPERIMENTAL
Intervention: FHIT, CatD, CatL, CD68, and CD83 levels
Number of subjects: 72
Study 32830215 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk scores (PRSs) based on multiple SNPs related to NT-proBNP, BNP, and MR-proANP
Number of subjects: 6669
Study 32830215 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk scores (PRSs)
Number of subjects: 6669
Study 32830215 — intervention group
Group type: EXPERIMENTAL
Intervention: Common genetic variation at the NPPA-NPPB locus
Number of subjects: 6669
Study 36159258 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of older women (≥35 years) in six urban slum communities with seven sessions on infant vaccination importance.
Number of subjects: 198
Study 36159258 — intervention group
Group type: COMPARATOR
Intervention: Control group with no training for older women.
Number of subjects: 198
Study 33831671 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-based deep learning algorithms for plaque characterization
Number of subjects: 598
Study 35876429 — intervention group
Group type: EXPERIMENTAL
Intervention: Low skill group
Number of subjects: 32
Study 35876429 — intervention group
Group type: COMPARATOR
Intervention: High skill group
Number of subjects: 32
Study 35876429 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall heart rate
Number of subjects: 32
Study 35876429 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary cortisol
Number of subjects: 32
Study 34138471 — intervention group
Group type: EXPERIMENTAL
Intervention: hyper-CVAD + ofatumumab
Number of subjects: 164
Study 34138471 — intervention group
Group type: COMPARATOR
Intervention: hyper-CVAD + Rituximab
Number of subjects: 164
Study 32223776 — intervention group
Group type: COMPARATOR
Intervention: Instructor-led training
Number of subjects: 21
Study 32223776 — intervention group
Group type: EXPERIMENTAL
Intervention: Video training
Number of subjects: 21
Study 35796997 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention, Commercial weight management Programme (WW) for 12 weeks
Number of subjects: 1267
Study 35796997 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention, Commercial weight management Programme (WW) for 52 weeks
Number of subjects: 1267
Study 35796997 — intervention group
Group type: COMPARATOR
Intervention: Weight loss vs. regain (secondary analysis)
Number of subjects: 1267
Study 34569941 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief web-based educational intervention
Number of subjects: 1660
Study 34569941 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1660
Study 35579535 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical mask during sniffin’ sticks test (SST)
Number of subjects: 20
Study 35579535 — intervention group
Group type: COMPARATOR
Intervention: No surgical mask during sniffin’ sticks test (SST)
Number of subjects: 20
Study 34187621 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g transgenic rice
Number of subjects: 0
Study 34187621 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g transgenic rice
Number of subjects: 0
Study 34187621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32572719 — intervention group
Group type: EXPERIMENTAL
Intervention: OMDI 0.002% (one drop once daily for 4 weeks)
Number of subjects: 26
Study 32572719 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005% (during 8-week run-in period)
Number of subjects: 26
Study 34997525 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assured eLearning
Number of subjects: 47
Study 34997525 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-reviewed published manuscripts
Number of subjects: 47
Study 34997525 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic preparation methods (various formats)
Number of subjects: 47
Study 34997525 — intervention group
Group type: EXPERIMENTAL
Intervention: PBP-based e-learning methodology
Number of subjects: 47
Study 33090294 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab therapy
Number of subjects: 0
Study 33090294 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab therapy in MI patients with uncontrolled familial hypercholesterolemia (FH)
Number of subjects: 0
Study 33090294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33580718 — intervention group
Group type: EXPERIMENTAL
Intervention: STRIDE intervention (multifactorial intervention to reduce serious fall injuries)
Number of subjects: 48
Study 32705832 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 84
Study 32705832 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 84
Study 32705832 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 84
Study 34217288 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback balance training using the Biodex Balance System
Number of subjects: 37
Study 34217288 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy participants)
Number of subjects: 37
Study 32936297 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 788
Study 32633141 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation (RDN)
Number of subjects: 18
Study 32633141 — intervention group
Group type: COMPARATOR
Intervention: Drug adjusted control
Number of subjects: 18
Study 35895759 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.2% hypertonic saline solution (HS)
Number of subjects: 8
Study 35895759 — intervention group
Group type: COMPARATOR
Intervention: 0.9% isotonic saline solution (IS)
Number of subjects: 8
Study 33788040 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher analytical reasoning
Number of subjects: 649
Study 33788040 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower analytical reasoning
Number of subjects: 649
Study 33788040 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytical reasoning
Number of subjects: 649
Study 33428463 — intervention group
Group type: EXPERIMENTAL
Intervention: Child and Adolescent Behavior Inventory (CABI) scales
Number of subjects: 2056
Study 33428463 — intervention group
Group type: EXPERIMENTAL
Intervention: CABI scales
Number of subjects: 2056
Study 33342710 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid titration protocols (target dose of 400 mg/day within 1 week)
Number of subjects: 75
Study 33342710 — intervention group
Group type: COMPARATOR
Intervention: Conventional weekly titration protocol (target dose of 400 mg/day in three weeks)
Number of subjects: 75
Study 33509957 — intervention group
Group type: EXPERIMENTAL
Intervention: Munich Breathlessness Service (MBS) attended for 5-6 weeks
Number of subjects: 183
Study 33509957 — intervention group
Group type: COMPARATOR
Intervention: Standard care for 8 weeks before starting MBS
Number of subjects: 183
Study 33308235 — intervention group
Group type: COMPARATOR
Intervention: EX+SIT (sitting 1-h, moderate-intensity walking 30-min, uninterrupted sitting 6.5-h)
Number of subjects: 67
Study 33308235 — intervention group
Group type: COMPARATOR
Intervention: EX+BR (sitting 1-h, moderate-intensity walking 30-min, sitting interrupted every 30-min with 3-min of light-intensity walking 6.5-h)
Number of subjects: 67
Study 33308235 — intervention group
Group type: COMPARATOR
Intervention: EX+SIT
Number of subjects: 67
Study 33308235 — intervention group
Group type: COMPARATOR
Intervention: EX+BR
Number of subjects: 67
Study 33461602 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled magnesium sulphate (5 cc of a 20% injectable vial or 2 cc of a 50% injectable vial diluted with 50 cc distilled water, nebulized via a mask) every eight hours for five days, in addition to standard treatment for COVID-19.
Number of subjects: 100
Study 33461602 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for COVID-19 only.
Number of subjects: 100
Study 33319792 — intervention group
Group type: EXPERIMENTAL
Intervention: Play&Grow program
Number of subjects: 54
Study 32798357 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT)
Number of subjects: 905
Study 32798357 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 905
Study 32393370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (0.5 mg/kg)
Number of subjects: 120
Study 32393370 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (10 mg/kg)
Number of subjects: 120
Study 36011907 — intervention group
Group type: EXPERIMENTAL
Intervention: Tart cherry juice (TCJ)
Number of subjects: 19
Study 36011907 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 19
Study 33316238 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 57
Study 33316238 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 57
Study 33219618 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive genomic profiling (CGP)
Number of subjects: 303
Study 33219618 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic alterations
Number of subjects: 303
Study 33219618 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor mutational burden (TMB)
Number of subjects: 303
Study 33219618 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsatellite instability (MSI)
Number of subjects: 303
Study 33219618 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed death-ligand 1 (PD-L1) positivity
Number of subjects: 303
Study 33219618 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic loss of heterozygosity (gLOH)
Number of subjects: 303
Study 33855673 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement call strategy
Number of subjects: 413
Study 36322461 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice slush (IS)
Number of subjects: 58
Study 36322461 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (sterile saline at room temperature)
Number of subjects: 58
Study 32940751 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg intravenous methylprednisolone (study group)
Number of subjects: 77
Study 32940751 — intervention group
Group type: COMPARATOR
Intervention: Saline solution as placebo (control group)
Number of subjects: 77
Study 32858399 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (4 g heptahydrate, infused over 30 min)
Number of subjects: 109
Study 32858399 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 109
Study 35083490 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviews (MI)
Number of subjects: 124
Study 33571652 — intervention group
Group type: COMPARATOR
Intervention: Superior plating (SP, n = 12)
Number of subjects: 24
Study 33571652 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual plating (DP, n = 12)
Number of subjects: 24
Study 33571652 — intervention group
Group type: COMPARATOR
Intervention: 3-point bending testing
Number of subjects: 24
Study 33571652 — intervention group
Group type: COMPARATOR
Intervention: Posterior torsional loading
Number of subjects: 24
Study 32698894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental Health Component (DHC) of the Index of Orthodontic Treatment Need (IOTN)
Number of subjects: 347
Study 32698894 — intervention group
Group type: EXPERIMENTAL
Intervention: Aesthetic Component (AC) of the Index of Orthodontic Treatment Need (IOTN)
Number of subjects: 347
Study 32698894 — intervention group
Group type: EXPERIMENTAL
Intervention: DHC categorization
Number of subjects: 347
Study 36239588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozonated-Oils Eyedrops
Number of subjects: 3546
Study 36239588 — intervention group
Group type: COMPARATOR
Intervention: Netilmycin eye drops
Number of subjects: 3546
Study 33361494 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed bodyweight resistance training
Number of subjects: 26
Study 33361494 — intervention group
Group type: COMPARATOR
Intervention: Moderate-speed bodyweight resistance training
Number of subjects: 26
Study 33720907 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine follow-up (synchronous face-to-face video)
Number of subjects: 150
Study 33720907 — intervention group
Group type: COMPARATOR
Intervention: Office-based follow-up
Number of subjects: 150
Study 33720907 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine follow-up
Number of subjects: 150
Study 33179993 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care based on the philosophy of HypnoBirthing
Number of subjects: 60
Study 33179993 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 32900208 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline personality disorder symptoms
Number of subjects: 606
Study 36114577 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal mindfulness practice
Number of subjects: 23
Study 36114577 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal mindfulness practice
Number of subjects: 23
Study 33601388 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR in females younger than 40 years
Number of subjects: 23041
Study 33601388 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR in males younger than 40 years
Number of subjects: 23041
Study 33601388 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR decline
Number of subjects: 23041
Study 33601388 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limit of eGFR at age ≥40 years
Number of subjects: 23041
Study 33601388 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limit of eGFR at age ≥65 years
Number of subjects: 23041
Study 35880281 — intervention group
Group type: COMPARATOR
Intervention: HT7
Number of subjects: 90
Study 35880281 — intervention group
Group type: COMPARATOR
Intervention: SP6
Number of subjects: 90
Study 35880281 — intervention group
Group type: EXPERIMENTAL
Intervention: HT7-SP6
Number of subjects: 90
Study 33513879 — intervention group
Group type: EXPERIMENTAL
Intervention: B12 supplementation (methylcobalamin) 1000 μg/day for one year
Number of subjects: 90
Study 33513879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 32843512 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance of endotracheal suction
Number of subjects: 249
Study 32843512 — intervention group
Group type: COMPARATOR
Intervention: Usual care including endotracheal suctioning
Number of subjects: 249
Study 34751591 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus fulvestrant (PAL + FUL)
Number of subjects: 0
Study 34751591 — intervention group
Group type: COMPARATOR
Intervention: Abemaciclib plus fulvestrant (ABEM + FUL)
Number of subjects: 0
Study 33893744 — intervention group
Group type: EXPERIMENTAL
Intervention: Active learning curriculum on well-being and happiness
Number of subjects: 515
Study 33893744 — intervention group
Group type: COMPARATOR
Intervention: Traditional psychology curriculum
Number of subjects: 515
Study 35836102 — intervention group
Group type: EXPERIMENTAL
Intervention: peg‐IFN‐α‐2b combined with TDF, GM‐CSF, and hepatitis B vaccine
Number of subjects: 303
Study 35836102 — intervention group
Group type: COMPARATOR
Intervention: peg‐IFN‐α‐2b plus TDF
Number of subjects: 303
Study 35836102 — intervention group
Group type: COMPARATOR
Intervention: interferon‐α‐2b alone
Number of subjects: 303
Study 34565664 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisite stereotactic radiation therapy (SBRT) alone
Number of subjects: 20
Study 34565664 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assurance (QA) using a benchmark case (BC)
Number of subjects: 20
Study 34565664 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical dosimetric analysis and quantitative geometric analysis
Number of subjects: 20
Study 36114701 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat-based MUST nursing intervention
Number of subjects: 120
Study 36114701 — intervention group
Group type: COMPARATOR
Intervention: Routine education and follow-up model (Control)
Number of subjects: 120
Study 32382082 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk additional chromosomal abnormalities (ACAs) at low blast levels (1-15%)
Number of subjects: 1510
Study 32382082 — intervention group
Group type: COMPARATOR
Intervention: Low-risk additional chromosomal abnormalities (ACAs) at low blast levels (1-15%)
Number of subjects: 1510